Sothema Expands Its Therapeutic Offerings by Incorporating Innovative Saffron-Based Solutions from Naali

Marrakech – On the sidelines of the 2026 edition of the Officine Expo, a key event for stakeholders in the pharmaceutical sector, Sothema and Naali have formalized a strategic agreement for the commercialization of Naali products by Sothema. This partnership marks a significant milestone in diversifying the therapeutic offerings of the Moroccan pharmaceutical group and opens new avenues for growth for both partners.

Leveraging Sothema’s industrial expertise, distribution capacity, and regional presence, this collaboration aims to accelerate the rollout of innovative solutions developed by Naali, a burgeoning brand that has established itself since its inception in 2020 with saffron-based dietary supplements, particularly focused on mental health and women’s well-being.

Through this agreement, Sothema reiterates its commitment to sustainable growth, rooted in innovation, scientific rigor, and the continuous diversification of its therapeutic areas. The integration of Naali’s solutions will enrich an already extensive portfolio, aligned with the evolving needs of health and well-being.

Meanwhile, Naali sees this collaboration as a major growth lever. The brand has built its identity around a strong belief: emotional stability should be accessible to all. Drawing on the virtues of saffron, often referred to as “red gold,” and employing an exclusive extraction method that captures key active compounds such as safranal and crocin, Naali offers targeted, transparent, and rigorous formulations aimed at guiding all generations towards sustainable emotional balance.

Founded in 1976, Sothema is now a key player in the production and commercialization of medications, dietary supplements, and medical devices. The group makes innovative treatments accessible in Morocco, Sub-Saharan Africa, and the Middle East, covering the majority of therapeutic areas through licensed products in partnership with around forty leading R&D laboratories, as well as generics and biosimilars developed under its own brands.

By combining scientific innovation, industrial expertise, and a shared vision of well-being, Sothema and Naali aim to transform this partnership into a sustainable value driver for patients and consumers, while also contributing to the proliferation of innovative health solutions derived from nature.